Drug Repositioning

Home
Services
Drug Repositioning

Drug Repositioning

Inquiry

Overview

Drug repositioning, also known as drug repurposing, is the process of identifying new therapeutic uses for existing drugs. It provides a cost-effective and time-saving approach to drug development by utilizing existing knowledge and resources. CD ComputaBio is a leading bioinformatics company specializing in drug repositioning services. With our cutting-edge technology and expertise in network pharmacology, we assist pharmaceutical companies in identifying potential drug candidates for new indications.

Figure 1. Process of Drug Repositioning. (Zhang Z, et al.2020)

Our Services

Our portfolio of drug repositioning services is designed to unlock the latent potential of existing compounds and provide novel strategies for identifying new therapies. Our services include:

Drug Repositioning

Leveraging advanced computational algorithms and data analysis, we uncover opportunities to repurpose known drugs for new indications, expanding their therapeutic applications and value.

Drug Repurpose

Through our specialized expertise, we provide comprehensive analysis and evaluation of existing drugs to identify promising candidates for repurposing, enabling the exploration of alternative indications and disease targets.

Drug Reprofile

Our in-depth profiling services assess the safety, pharmacokinetics, and pharmacodynamics of existing drugs, guiding the identification of new uses or optimizing their therapeutic properties for enhanced efficacy.

Drug Redirecting

We offer innovative strategies to redirect drug candidates toward new targets or pathways, maximizing their potential to address diverse diseases and biological mechanisms.

Network Pharmacology Service

Our network pharmacology services integrate multi-omics data and advanced network analysis to elucidate the complex interactions between drugs, targets, and pathways, enabling a comprehensive understanding of drug mechanisms and potential repositioning opportunities.

Figure 2. Our Network Pharmacology Service.

Applications

The drug repositioning services offered by CD ComputaBio have broad applications across the pharmaceutical industry. They can aid in:

Identifying new therapeutic uses for existing drugs, reducing the time and cost required for drug development.
Repurposing failed drugs for alternative indications, maximizing their potential, and minimizing financial losses.
Personalizing treatment regimens by identifying subgroups of patients who would benefit from specific drugs.

Algorithms

At CD ComputaBio, we employ a range of computational algorithms and methods to maximize the effectiveness of our drug repositioning services. These include

Figure 2. Drug Repositioning Service.

Network-based approaches: Apply network pharmacology strategies to predict drug-target interactions and reveal potential repurposing opportunities.
Machine learning techniques: Utilizing algorithms such as random forests and support vector machines to analyze large-scale omics data and predict drug-disease associations.

Sample Requirements

To provide the highest quality drug repositioning services, we require specific sample information, including:

Sample Requirements	Descriptions
Drug compounds	The chemical structures and properties of the drugs to be analyzed.
Disease profiles	Detailed information regarding the diseases or indications of interest.
Patient data	Genetic, genomic, or clinical data relevant to the analysis, if available.

Deliverables

Sample Requirements	Descriptions
Comprehensive reports	Detailed findings, analysis, and interpretations of the drug repositioning studies.
Candidate drug lists	Recommendations of potential drug candidates for new indications.
Experimental validation guidelines	Suggestions for experimental validations to confirm the effectiveness of the repurposed drugs.
Network visualization	Interactive visual representations of biological networks to aid in further analysis and decision-making.

Why Choose Us?

CD ComputaBio stands at the forefront of drug repositioning services, offering a comprehensive range of solutions to pharmaceutical companies. We utilize network pharmacology and advanced computational algorithms to help identify new therapeutic uses for existing drugs, optimize therapeutic regimens, and improve the success of drug development.

Frequently Asked Questions

How is a potential drug candidate identified for repositioning?

Drug candidates for repositioning can be identified through various means. One common approach is by analyzing the off-target effects of existing drugs. These are the unintended interactions of a drug with other molecules or pathways in the body that were not the primary target for its original indication. For example, a drug developed to treat hypertension might be found to have unexpected effects on cancer cells during preclinical studies, suggesting a potential role in cancer treatment. Another method is to look for similarities in the disease pathways. If a drug is known to target a particular biological pathway that is also implicated in another disease, it could be a candidate for repositioning.

What role does CADD play in drug repositioning?

Computer-Aided Drug Design (CADD) is highly valuable in drug repositioning. It can help in predicting the potential interactions of a drug with new targets based on its chemical structure and known binding properties. Molecular docking simulations can be used to assess whether a drug molecule can fit into the binding sites of proteins associated with other diseases. CADD can also analyze large datasets to identify patterns and correlations that suggest potential repositioning opportunities. For instance, it can compare the structures of drugs that are effective against a particular disease with those of existing drugs to predict which ones might have similar activities.

What are the challenges in validating the new indication of a repositioned drug?

Validating a new indication for a repositioned drug can be challenging. One of the main difficulties is establishing the appropriate dosing and administration regimens. Since the drug was originally developed for a different condition, the optimal dosage and schedule for the new indication might be different and need to be determined through clinical trials. Another challenge is demonstrating efficacy in the new context. The disease models and endpoints used in the original trials might not be directly applicable to the new indication, requiring the development of new biomarkers and clinical outcome measures. Regulatory requirements for demonstrating safety and efficacy for the new use can also be complex and demanding.

How are intellectual property and patent issues managed in drug repositioning?

Intellectual property and patent issues in drug repositioning can be complex. If a drug is still under patent protection for its original indication, obtaining rights for the new indication might involve negotiations with the patent holder or licensing agreements. In some cases, the patent might have expired for the original use, making it easier to pursue the new indication without significant patent-related barriers. However, there can be disputes over whether the new use is truly novel and deserving of separate patent protection. This requires careful legal and scientific analysis to determine the extent of novelty and inventiveness associated with the repositioned application.

What are the ethical considerations in drug repositioning?

Ethical considerations in drug repositioning include ensuring that the new use is based on sound scientific evidence and that patients are not exposed to unnecessary risks. There is also the issue of equitable access to repositioned drugs, especially if they become highly valuable for a new indication and pricing becomes a barrier for certain patient populations. Informed consent is crucial when conducting clinical trials for the new indication, as patients need to understand the potential benefits and risks, especially given that the drug is already in use for another purpose. Additionally, there might be ethical questions regarding the allocation of research resources and whether efforts should be focused on repositioning existing drugs or developing completely new treatments.

Reference

Zhang Z, Zhou L, Xie N, et al. Overcoming cancer therapeutic bottleneck by drug repurposing[J]. Signal transduction and targeted therapy, 2020, 5(1): 113.

For research use only. Not intended for any clinical use.

Drug Repositioning

Overview

Our Services

Applications

Algorithms

Sample Requirements

Deliverables

Why Choose Us?

Frequently Asked Questions

Related Services

Online Inquiry